[1]祝 静,龙思琪,蒋 瑶,等.川东北地区MM患者骨髓瘤细胞免疫表型特征及其临床意义[J].医学信息,2021,34(10):88-91.[doi:10.3969/j.issn.1006-1959.2021.10.024]
　ZHU Jing,LONG Si-qi,JIANG Yao,et al.Immune Phenotype Characteristics and Clinical Significance of Myeloma Cells in Patients with MM in Northeastern Sichuan[J].Medical Information,2021,34(10):88-91.[doi:10.3969/j.issn.1006-1959.2021.10.024]
点击复制

川东北地区MM患者骨髓瘤细胞免疫表型特征及其临床意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年10期
页码:
88-91
栏目:
论著
出版日期:
2021-05-15

文章信息/Info

Title:
Immune Phenotype Characteristics and Clinical Significance of Myeloma Cells in Patients with MM in Northeastern Sichuan
文章编号:
1006-1959（2021）10-0088-04
作者:
祝 静; 龙思琪; 蒋 瑶; 等
（1.川北医学院医学检验系，四川 南充 637000；2.川北医学院附属医院检验科，四川 南充 637000；3.川北医学院附属医院血液科，四川 南充 637000）
Author(s):
ZHU Jing; LONG Si-qi; JIANG Yao; et al.
(1.Department of Medical Laboratory Science,North Sichuan Medical College,Nanchong 637000, Sichuan,China;2.Department of Laboratory Medicine,Affiliated Hospital of North Sichuan Medical College, Nanchong 637000,Sichuan,China;3.Department of Hematology,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan,China)
关键词:
多发性骨髓; 免疫表型; 血液肿瘤
Keywords:
Multiple myeloma; Immunophenotype; Hematological tumors
分类号:
R733.3
DOI:
10.3969/j.issn.1006-1959.2021.10.024
文献标志码:
A
摘要:
目的 明确我国川东北地区多发性骨髓（MM）患者骨髓瘤细胞免疫表型的特征及其临床意义。方法 流式细胞术检测川北医学院附属医院2018年1月~2020年1月血液科住院的MM患者骨髓瘤细胞的免疫表型，分析CD38、CD138、CD19、CD56、CD20、CD117、CD27、CD28、CD33、cKappa、cLambda在不同临床分期之间表达率的差异以及其与病情评估指标LDH、白蛋白、β2-MG、血红蛋白的关系。结果 川东北地区MM患者骨髓瘤细胞CD分子的阳性表达率从高到低依次为CD38（100.00%）、CD138（100.00%）、CD56（77.88%）、CD19（55.77%）、cLambda（55.77%）、CD28（54.81%）、CD117（48.28%）、CD27（44.23%）、cKappa（44.23%）、CD33（26.92%）、CD20（21.15%）。ISS不同分期CD27的阳性表达率比较，差异有统计学意义（P＜0.05）；CD56+组LDH、白蛋白低于D56-组，CD117+组白蛋白水平高于CD117-组，CD27+组β2-MG低于CD27-组，CD28+组的血红蛋白高于CD28-组（P＜0.05）；CD19+组与CD19-组、CD20+组与CD20-组及CD33+组与CD33-组血清LDH、β2-MG、白蛋白及血红蛋白分别比较，差异无统计学意义（P＞0.05）。结论 骨髓瘤细胞的免疫表型具有高度异质性和地域差异，CD27的表达阳性率越低，ISS分期越晚，可能病情更重。CD27+、CD56+、CD117+及CD28+患者的疾病活动度、肿瘤负荷、肿瘤消耗及瘤细胞可能对骨髓的浸润及抑制程度均分别的低于相应的阴性患者。
Abstract:
Objective To clarify the characteristics and clinical significance of the immunophenotype of myeloma cells in patients with multiple myeloma(MM) in northeastern Sichuan.Methods Flow cytometry was used to detect the immunophenotype of myeloma cells in MM patients hospitalized in the Department of Hematology from January 2018 to January 2020 in the Affiliated Hospital of North Sichuan Medical College.Analyzing the differences in the expression rates of CD38, CD138, CD19, CD56, CD20, CD117, CD27, CD28, CD33, cKappa, and cLambda between different clinical stages and their relationship with disease evaluation indicators LDH, albumin, β2-MG, and hemoglobin.Results The positive expression rate of CD molecules in myeloma cells of MM patients in Northeast Sichuan was CD38 (100.00%), CD138 (100.00%), CD56 (77.88%), CD19 (55.77%), and cLambda (55.77%), CD28 (54.81%), CD117 (48.28%), CD27 (44.23%), cKappa (44.23%), CD33 (26.92%), CD20 (21.15%).The positive expression rate of CD27 in different stages of ISS was compared,the difference was statistically significant (P＜0.05);CD56+ group LDH and albumin were lower than D56- group, CD117+ group albumin level was higher than CD117- group, CD27+ group β2-MG was lower than CD27- group, CD28+ group had higher hemoglobin than CD28- group (P＜0.05);There was no significant difference in serum LDH, β2-MG, albumin and hemoglobin between CD19+ group and CD19- group, CD20+ group and CD20- group, and CD33+ group and CD33- group respectively (P＞0.05).Conclusion The immunophenotype of myeloma cells is highly heterogeneous and regionally different. The lower the positive rate of CD27 expression, the later the stage of ISS, and the more severe the disease may be. CD27+, CD56+, CD117+ and CD28+ patients’ disease activity, tumor burden, tumor wasting, and tumor cell infiltration and inhibition of bone marrow may be lower than the corresponding negative patients.

参考文献/References:

[1]葛均波,徐永健,王辰.内科学[M].第九版,北京:人民卫生出版社,2018:592-595.[2]Schouweiler KE,Karandikar NJ,Holman CJ.Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry[J].Cytometry B Clin Cytom,2019,96(4):310-318.[3]Sonneveld P,Broijl A.Treatment of relapsed and refractory multiple myeloma[J].Haematologica,2016,101(4):396-397.[4]常子维,朱华峰,冯苗娟,等.160例多发性骨髓瘤患者免疫表型特征及其临床意义[J].现代生物医学进展,2016,16(26):5179-5183.[5]Iii HRB,Dasari S,Dispenzieri A,et al.Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma Without Bone Marrow Aspirates[J].Clinical Chemistry,2016,62(1):243-251.[6]许超平,周涛,胡桂英,等.vdac-1基因调控多发性骨髓瘤细胞表达髓系分化抗原CD33实验研究[J].临床血液学杂志,2017,30(5):368-371.[7]Remedios KA,Meyer L,Zirak B,et al.CD27 Promotes CD4+ Effector T Cell Survival in Response to Tissue Self-Antigen[J].J Immunol,2019,203(3):639-646.[8]Maiso P,Huynh D,Moschetta M,et al.Metabolic signature identifies novel targets for drug resistance in multiple myeloma[J].Cancer Res,2015,75(10):2071-2082.[9]段丽娟,李超,杨如玉.多发性骨髓瘤患者血清β2-微球蛋白、TNF-α、CRP及IL-6水平检测[J].中国实验血液学杂志,2015,23(5):1362-1365.[10]Chu B,Bao L,Wang Y,et al.CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma[J].Clin Immunol,2020(213):108363.

相似文献/References:

[1]岳永威,孔令军.儿童急性早幼粒细胞白血病的免疫表型特点分析[J].医学信息,2021,34(23):36.[doi:10.3969/j.issn.1006-1959.2021.23.010]
　YUE Yong-wei,KONG Ling-jun.Analysis of Immunophenotypic Characteristics of Children with Acute Promyelocytic Leukemia[J].Medical Information,2021,34(10):36.[doi:10.3969/j.issn.1006-1959.2021.23.010]
[2]邓 娜,吴冠宇,杨 柳,等.流式细胞术在多发性骨髓瘤治疗中的应用价值[J].医学信息,2022,35(02):75.[doi:10.3969/j.issn.1006-1959.2022.02.018]
　DENG Na,WU Guan-yu,YANG Liu,et al.Application Value of Flow Cytometry in the Treatment of Multiple Myeloma[J].Medical Information,2022,35(10):75.[doi:10.3969/j.issn.1006-1959.2022.02.018]

更新日期/Last Update: 1900-01-01